Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T cells for CNS involvement in B-ALL and B-NHL
NCT04532203Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of LV20.19 CAR-T in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Zhejiang University. Primary endpoint: Dose-limiting toxicity at 28 days. Started Nov 2020; status: recruiting.
02
Drugs
LV20.19 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT04532203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532203.